318 related articles for article (PubMed ID: 24053552)
1. Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis.
Passoni NM; Fajkovic H; Xylinas E; Kluth L; Seitz C; Robinson BD; Rouprêt M; Chun FK; Lotan Y; Roehrborn CG; Crivelli JJ; Karakiewicz PI; Scherr DS; Rink M; Graefen M; Schramek P; Briganti A; Montorsi F; Tewari A; Shariat SF
BJU Int; 2014 Oct; 114(4):503-10. PubMed ID: 24053552
[TBL] [Abstract][Full Text] [Related]
2. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?
Kluth LA; Xylinas E; Rieken M; Chun FK; Fajkovic H; Becker A; Karakiewicz PI; Passoni N; Herman M; Lotan Y; Seitz C; Schramek P; Remzi M; Loidl W; Guillonneau B; Rouprêt M; Briganti A; Scherr DS; Graefen M; Tewari AK; Shariat SF
Urol Oncol; 2014 Jan; 32(1):47.e1-8. PubMed ID: 24055425
[TBL] [Abstract][Full Text] [Related]
3. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.
Fajkovic H; Cha EK; Jeldres C; Robinson BD; Rink M; Xylinas E; Chromecki TF; Breinl E; Svatek RS; Donner G; Tagawa ST; Tilki D; Bastian PJ; Karakiewicz PI; Volkmer BG; Novara G; Joual A; Faison T; Sonpavde G; Daneshmand S; Lotan Y; Scherr DS; Shariat SF
Eur Urol; 2013 Nov; 64(5):837-45. PubMed ID: 22877503
[TBL] [Abstract][Full Text] [Related]
4. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score.
Schiavina R; Borghesi M; Brunocilla E; Manferrari F; Fiorentino M; Vagnoni V; Baccos A; Pultrone CV; Rocca GC; Rizzi S; Martorana G
BJU Int; 2013 Jun; 111(8):1237-44. PubMed ID: 23331345
[TBL] [Abstract][Full Text] [Related]
5. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
7. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
[TBL] [Abstract][Full Text] [Related]
8. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
[TBL] [Abstract][Full Text] [Related]
9. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.
Boormans JL; Wildhagen MF; Bangma CH; Verhagen PC; van Leenders GJ
BJU Int; 2008 Dec; 102(11):1589-93. PubMed ID: 18710447
[TBL] [Abstract][Full Text] [Related]
10. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience.
Pierorazio PM; Gorin MA; Ross AE; Feng Z; Trock BJ; Schaeffer EM; Han M; Epstein JI; Partin AW; Walsh PC; Bivalacqua TJ
Prostate; 2013 Nov; 73(15):1673-80. PubMed ID: 24019101
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival.
Fleischmann A; Schobinger S; Markwalder R; Schumacher M; Burkhard F; Thalmann GN; Studer UE
Histopathology; 2008 Oct; 53(4):468-75. PubMed ID: 18764879
[TBL] [Abstract][Full Text] [Related]
12. Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study.
Mozzillo N; Pasquali S; Santinami M; Testori A; Di Marzo M; Crispo A; Patuzzo R; Verrecchia F; Botti G; Montella M; Rossi CR; Caracò C
Eur J Surg Oncol; 2015 Jul; 41(7):823-9. PubMed ID: 25800935
[TBL] [Abstract][Full Text] [Related]
13. Association between Lymph Node Counts and Oncological Outcomes in Lymph Node Positive Prostate Cancer.
Mandel P; Kriegmair MC; Bogdan K; Boehm K; Budäus L; Graefen M; Huland H; Tilki D
Eur Urol Focus; 2017 Apr; 3(2-3):248-255. PubMed ID: 28753755
[TBL] [Abstract][Full Text] [Related]
14. Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes.
Ledezma RA; Negron E; Razmaria AA; Dangle P; Eggener SE; Shalhav AL; Zagaja GP
World J Urol; 2015 Nov; 33(11):1689-94. PubMed ID: 25701128
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
16. Extranodal extension in lymph node-positive prostate cancer.
Cheng L; Pisansky TM; Ramnani DM; Leibovich BC; Cheville JC; Slezak J; Bergstralh EJ; Zincke H; Bostwick DG
Mod Pathol; 2000 Feb; 13(2):113-8. PubMed ID: 10697266
[TBL] [Abstract][Full Text] [Related]
17. Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection.
Passoni NM; Abdollah F; Suardi N; Gallina A; Bianchi M; Tutolo M; Fossati N; Gandaglia G; Salonia A; Freschi M; Rigatti P; Montorsi F; Briganti A
Urol Oncol; 2014 Jan; 32(1):29.e21-8. PubMed ID: 23490908
[TBL] [Abstract][Full Text] [Related]
18. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
[TBL] [Abstract][Full Text] [Related]
19. Algorithm for selecting men for pelvic lymph node dissection (PLND) during radical prostatectomy based on clinical risk factors in an Australian population.
Sengupta S; Weerakoon M; Sethi K; Ischia J; Webb DR
BJU Int; 2012 Apr; 109 Suppl 3():48-51. PubMed ID: 22458494
[TBL] [Abstract][Full Text] [Related]
20. Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection.
Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
Clin Cancer Res; 2018 May; 24(10):2342-2349. PubMed ID: 29463560
[No Abstract] [Full Text] [Related]
[Next] [New Search]
